5 - Contents

6-7 NEWS
Biogen to acquire Reata for $7.3bn; Sandoz’s Tyruko approved by FDA for relapsing MS

8-9 NEWS
Pfizer/BioNTech’s updated COVID-19 vaccine approved by EC; UK invests £210m to fight AMR

10-11 DERMATOLOGY NEWS
BMS's Opdivo approved by EC; Moderna and Merck’s skin cancer vaccine enters late-stage development

12 DARWIN'S MEDICINE
Why you and your company may be worse, rather than better, than you used to be

13 POLICY AND PUBLIC HEALTH
Your doctor’s administrative burden is a public health crisis

14 BEING HEALTHY
Insights from this year’s annual Edelman Trust Barometer health data

15 INNOVATIVE IMPACT BLOG
Seven steps to exceptional launches

16-17 THE IMPACT OF PROSTATE CANCER ON GLOBAL HEALTH
Noel Clarke talks to PME about current research for prostate cancer and how treatments have improved over the last decade

18-19 MAN VS MICROBE: THE FIGHT AGAINST ANTIMICROBIAL RESESTANCE
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics

20-21 ACTINIC KERATOSIS – A COMMON SKIN CONDITION THAT CAN LEAD TO SKIN CANCER
Volker Koscielny, CMO at Almirall, talks about the importance of skin checks to protect against skin cancer

24-26 THE FIVE ‘INNOVATION AREAS’ DRIVING SUCCESS IN CHRONIC DISEASES
As brands leverage the power of creativity to make a meaningful difference to lives and their businesses, pharma is finally making a splash on the French Riviera

30-32 THE IMPORTANCE OF ACCELERATING CLINICAL TRIAL DIVERSITY
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour

34-35 HARNESSING THE POWER OF AI I N CLINICAL TRIALS
Fareed Melhem talks about how artificial intelligence can help to reduce the burden of trials on patients

37 LIFEARC TO LAUNCH ‘TRANSLATIONAL RARE DISEASE CENTRES’ ACROSS THE UK
Medical research organisation and charity LifeArc has announced the launch of a new programme that will invest more than £100m by 2030 in a bid to improve the lives of people living with a rare disease

41 HEALTHCARE COMMS
Havas acquires majority stake in Uncommon; OPEN Health announces new team to lead HEOR and Market Access Scientific Office

September 2023